Trial Profile
An Open-Label, Two-Part, Multi-Centre, Trastuzumab Dose-Finding Study in Healthy Male Volunteers and HER2 Positive Female Patients
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Trastuzumab (Primary) ; Trastuzumab (Primary)
- Indications Advanced breast cancer; HER2 positive breast cancer; Male breast cancer
- Focus Pharmacokinetics
- Sponsors Roche
- 22 Feb 2012 Results published in the Journal of Clinical Pharmacology.
- 15 Jul 2010 Actual end date changed from Nov 2009 to June 2010 as reported by ClinicalTrials.gov.
- 13 Jul 2010 Status changed from active, no longer recruiting to completed as reported by Roche record.